Bloomsbury Genetic Therapies Limited, a biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, has announced its launch with £5 million Seed financing led by UCL Technology Fund.
Bloomsbury’s innovative approach is designed to optimise therapeutic efficacy and safety, enable high manufacturability, accelerate development timelines and maximise regulatory success to create a pipeline of highly differentiated first- or best-in-class programs. The Company’s lead programs are liver and CNS targeted gene therapies.
Bloomsbury Genetic Therapies is a great example of the innovative opportunities that UCL Technology Fund seeks to spin out from the university, where we bring together an exceptional team of world-class leaders in their respective fields. We are excited by the potential to develop the best-in-class products which target neurometabolic conditions, where there are no other treatment options. Leigh Brody, Investor, UCLTF
Bloomsbury Genetic Therapies is a great example of the innovative opportunities that UCL Technology Fund seeks to spin out from the university, where we bring together an exceptional team of world-class leaders in their respective fields. We are excited by the potential to develop the best-in-class products which target neurometabolic conditions, where there are no other treatment options.
Read the full story from Bloomsbury.
We make UCL’s research physical and life sciences ideas happen.
